Mike Egan serves as the Vice President of Neuroscience at Merck, where he leads global clinical development. His expertise spans psychiatry, drug development, and translational medicine, backed by a residency at the University of Colorado and a fellowship at the National Institute of Mental Health.
His research on the genetic effects of COMT on human cognition and schizophrenia was cited by Science in 2003 as a runner-up for "Breakthrough of the Year. "
Read the full overview →Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.